Advertisement

An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use

  • Alan J. Budney
  • Michael J. Sofis
  • Jacob T. Borodovsky
Invited Review
  • 84 Downloads

Abstract

Confusion and controversy related to the potential for cannabis use to cause harm, or alternatively to provide benefit, continues globally. This issue has grown in intensity and importance with the increased recognition of the public health implications related to the escalation of the legalization of cannabis and cannabinoid products. This selective overview and commentary attempt to succinctly convey what is known about one potential consequence of cannabis use, the development of cannabis use disorder (CUD). Such knowledge may help guide a reasonable and objective public health perspective on the potential impact of cannabis use and CUD. Current scientific data and clinical observation strongly support the contention that cannabis use, like the use of other substances such as alcohol, opioids, stimulants, and tobacco, can develop into a use disorder (addiction) with important clinical consequences. Epidemiological data indicate that the majority of those who use cannabis do not have problems related to their use, but a substantial subset (10–30%) do report experiencing symptoms and consequences consistent with a CUD. Treatment seeking for CUD comprises a substantial proportion of all substance use treatment admissions, yet treatment response rates show much room for improvement. Changing cannabis policies related to its therapeutic and recreational use are likely to impact the development of CUD and its course; however, definitive data on such effects are not yet available. Clearly, the development of more effective prevention and treatment strategies is needed for those vulnerable to developing a CUD and for those with a CUD.

Keywords

Cannabis Cannabis use disorder Marijuana Policy Prevalence Treatment Legalization 

Notes

Compliance with ethical standards

Conflict of interest

Neither author has any conflicts of interest other than research and training support from the NIH-NIDA.

References

  1. 1.
    World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. World Health Organization, GenevaGoogle Scholar
  2. 2.
    Zehra A, Burns J, Kure Liu C, Manza P, Wiers C, Volkow N, Wang G (2018) Cannabis addiction and the brain: a review. J Neuroimmune Pharmacol 1–15.  https://doi.org/10.1007/s11481-018-9782-9
  3. 3.
    APA (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, ArlingtonGoogle Scholar
  4. 4.
    Budney AJ, Roffman R, Stephens RS, Walker D (2007) Marijuana dependence and its treatment. Addict Sci Clin Pract 4(1):4–16CrossRefGoogle Scholar
  5. 5.
    Bloomfield MAP, Ashok AH, Volkow ND, Howes OD (2016) The effects of ∆9-tetrahydrocannabinol on the dopamine system. Nature 539:369.  https://doi.org/10.1038/nature20153 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Vandrey R, Haney M (2009) Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 23(7):543–553CrossRefGoogle Scholar
  7. 7.
    ElSohly (2005) Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 78:539–548CrossRefGoogle Scholar
  8. 8.
    Budney AJ, Lile JA (2009) Moving beyond the cannabis controversy into the world of the cannabinoids. Int Rev Psychiatry 21(2):91–95.  https://doi.org/10.1080/09540260902782729 CrossRefPubMedGoogle Scholar
  9. 9.
    Budney AJ, Borodovsky JT (2017) The potential impact of cannabis legalization on the development of cannabis use disorders. Prev Med.  https://doi.org/10.1016/j.ypmed.2017.06.034 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z (2008) Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat 35(4):362–368.  https://doi.org/10.1016/j.jsat.2008.01.002 pii]CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, Zhang H, Grant BF (2016) Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions–III. Am J Psychiatry 173(6):588–599.  https://doi.org/10.1176/appi.ajp.2015.15070907 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    WHO (2016) The Health and social effects of nonmedical cannabis use. Geneva, SwitzerlandGoogle Scholar
  13. 13.
    UNODC (2018) World drug report: pre-briefing to the member states. United Nations Office on Drugs and Crime, ViennaGoogle Scholar
  14. 14.
    SAMHSA (2017) Results from the 2016 national survey on drug use and health: detailed tables. Prevalence estimates, standard Errors, P Values, and sample sizes. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, RockvilleGoogle Scholar
  15. 15.
    Mauro PM, Carliner H, Brown QL, Hasin DS, Shmulewitz D, Rahim-Juwel R, Sarvet AL, Wall MM, Martins SS (2018) Age differences in daily and nondaily cannabis use in the United States, 2002–2014. J Stud Alcohol Drugs 79(3):423–431.  https://doi.org/10.15288/jsad.2018.79.423 CrossRefPubMedGoogle Scholar
  16. 16.
    Degenhardt L, Ferrari AJ, Calabria B, Hall W, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T (2013) The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 Study. Plos ONE 8(10):e76635.  https://doi.org/10.1371/journal.pone.0076635 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pabst A, Kraus L, Gomes de Matos E, Piontek D (2013) Substance use and substance use disorders in Germany in 2012. SUCHT 59:321–331CrossRefGoogle Scholar
  18. 18.
    Teesson M, Slade T, Swift W, Mills K, Memedovic S, Mewton L, Grove R, Newton N, Hall W (2012) Prevalence, correlates and comorbidity of DSM-IV cannabis use and cannabis use disorders in Australia. Aust N Z J Psychiatry 46(12):1182–1192CrossRefGoogle Scholar
  19. 19.
    Grucza RA, Agrawal A, Bierut LJ (2016) NESARC Findings on increased prevalence of marijuana use disorders—reply consistent with other sources of information. JAMA Psychiatry 73(5):532–533.  https://doi.org/10.1001/jamapsychiatry.2016.0244 CrossRefPubMedGoogle Scholar
  20. 20.
    Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF (2015) Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 72(12):1235–1242.  https://doi.org/10.1001/jamapsychiatry.2015.1858 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ (2016) Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry 73(3):300–301.  https://doi.org/10.1001/jamapsychiatry.2015.3111 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, Jung J, Zhang H, Fan A, Hasin DS (2017) Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry 74(9):911–923.  https://doi.org/10.1001/jamapsychiatry.2017.2161 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chou SP, Goldstein RB, Smith SM, Huang B, Ruan WJ, Zhang H, Jung J, Saha TD, Pickering RP, Grant BF (2016) The epidemiology of DSM-5 nicotine use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. J Clin Psychiatry 77(10):1404–1412.  https://doi.org/10.4088/JCP.15m10114 CrossRefPubMedGoogle Scholar
  24. 24.
    Budney AJ (2006) Are specific dependence criteria necessary for different substances: how can research on cannabis inform this issue? Addiction 101:125–133CrossRefGoogle Scholar
  25. 25.
    Shmulewitz D, Greene ER, Hasin D (2015) Commonalities and differences across substance use disorders: phenomenological and epidemiological aspects. Alcohol Clin Exp Res 39(10):1878–1900.  https://doi.org/10.1111/acer.12838 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Budney AJ, Hughes JR (2006) The cannabis withdrawal syndrome. Curr Opin Psychiatry 19(3):233–238CrossRefGoogle Scholar
  27. 27.
    Peer K, Rennert L, Lynch KG, Farrer L, Gelernter J, Kranzler HR (2013) Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample. Drug Alcohol Depend 127(0):215–219CrossRefGoogle Scholar
  28. 28.
    Kerridge BT, Pickering R, Chou P, Saha TD, Hasin DS (2018) DSM-5 cannabis use disorder in the national epidemiologic survey on alcohol and related conditions-III: gender-specific profiles. Addict Behav 76:52–60CrossRefGoogle Scholar
  29. 29.
    Kimbrel N, Meyer E, DeBeer B, Gulliver S, Morissette S (2018) The impact of cannabis use disorder on suicidal and nonsuicidal self-injury in Iraq/Afghanistan-era veterans with and without mental health disorders. Suicide Life Threat Behav 48(2):140–148CrossRefGoogle Scholar
  30. 30.
    Campbell CI, Bahorik AL, Kline-Simon AH, Satre DD (2017) The role of marijuana use disorder in predicting emergency department and inpatient encounters: a retrospective cohort study. Drug Alcohol Depend 178:170–175CrossRefGoogle Scholar
  31. 31.
    Crean RD, Crane NA, Mason BJ (2011) An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 5(1):1–8.  https://doi.org/10.1097/ADM.0b013e31820c23fa CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kowal MA, van Steenbergen H, Colzato LS, Hazekamp A, van der Wee NJA, Manai M, Durieux J, Hommel B (2015) Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users. Eur Neuropsychopharmacol 25(11):1943–1953CrossRefGoogle Scholar
  33. 33.
    Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73(3):292–297.  https://doi.org/10.1001/jamapsychiatry.2015.3278 CrossRefPubMedGoogle Scholar
  34. 34.
    Solowij N, Battisti R (2008) The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 1(1):81–98CrossRefGoogle Scholar
  35. 35.
    Lorenzetti V, Alonso-Lana S, Youssef GJ, Verdejo-Garcia A, Suo C, Cousijn J, Takagi M, Yücel M, Solowij N (2016) Adolescent cannabis use: what is the evidence for functional brain alteration? Curr Pharm Des 22(42):6353–6365.  https://doi.org/10.2174/1381612822666160805155922 CrossRefPubMedGoogle Scholar
  36. 36.
    Jernigan TL, Brown SA, Coordinators AC (2018) Introduction. Dev Cogn Neurosci 32: The Adolescent Brain Cognitive Development (ABCD) Consortium: Rationale, aims, and assessment strategy:1–3Google Scholar
  37. 37.
    Farmer RFK, Seeley DB, Gau JR, Duncan JM, Walker SC, Lewinsohn DD PM (2016) Association of comorbid psychopathology with the duration of cannabis use disorders. Psychol Addict Behav 30(1):82–92CrossRefGoogle Scholar
  38. 38.
    Agrawal A, Budney AJ, Lynskey MT (2012) The co-occurring use and misuse of cannabis and tobacco: a review. Addiction.  https://doi.org/10.1111/j.1360-0443.2012.03837.x CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Lee DC, Budney AJ, Brunette MF, Hughes JR, Etter JF, Stanger C (2015) Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use. Drug Alcohol Depend 155:134–140.  https://doi.org/10.1016/j.drugalcdep.2015.08.001 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Florez-Salamanca L, Secades-Villa R, Hasin DS, Cottler L, Wang S, Grant BF, Blanco C (2013) Probability and predictors of transition from abuse to dependence on alcohol, cannabis, and cocaine: results from the national epidemiologic survey on alcohol and related conditions. Am J Drug Alcohol Abuse 39(3):168–179CrossRefGoogle Scholar
  41. 41.
    Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J (2013) Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry 54(6):589–598CrossRefGoogle Scholar
  42. 42.
    Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C (2011) Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). Drug Alcohol Depend 115(1–2):120–130.  https://doi.org/10.1016/j.drugalcdep.2010.11.004 CrossRefPubMedGoogle Scholar
  43. 43.
    Martins SS, Gorelick DA (2011) Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend 119(1–2):28–36CrossRefGoogle Scholar
  44. 44.
    Cheung JT, Mann RE, Ialomiteanu A, Stoduto G, Chan V, Ala-Leppilampi K, Rehm J (2010) Anxiety and mood disorders and cannabis use. Am J Drug Alcohol Abuse 36(2):118–122.  https://doi.org/10.3109/00952991003713784 CrossRefPubMedGoogle Scholar
  45. 45.
    Zvolensky MJ, Cougle JR, Johnson KA, Bonn-Miller MO, Bernstein A (2010) Marijuana use and panic psychopathology among a representative sample of adults. Exp Clin Psychopharmacol 18(2):129–134.  https://doi.org/10.1037/a0019022 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Degenhardt L, Hall W, Lynskey M (2001) The relationship between cannabis use, depression and anxiety among Australian adults: findings from the national survey of mental health and well-being. Soc Psychiatry Psychiatr Epidemiol 36(5):219–227. doi: https://doi.org/10.1007/s001270170052 CrossRefPubMedGoogle Scholar
  47. 47.
    Stinson FS, Ruan WJ, Pickering R, Grant BF (2006) Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 36(10):1447–1460.  https://doi.org/10.1017/S0033291706008361 CrossRefPubMedGoogle Scholar
  48. 48.
    Borodovsky JT, Budney AJ (2018) Cannabis regulatory science: risk–benefit considerations for mental disorders. Int Rev Psychiatry:1–20.  https://doi.org/10.1080/09540261.2018.1454406
  49. 49.
    Goldenberg M, Reid MW, IsHak WW, Danovitch I (2017) The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: a systematic review and meta-analysis. Drug Alcohol Depend 174:80–90CrossRefGoogle Scholar
  50. 50.
    Montanari L, Guarita B, Mounteney J, Zipfel N, Simon R (2017) Cannabis use among people entering drug treatment in Europe: a growing phenomenon? Eur Addict Res 23(3):113–121CrossRefGoogle Scholar
  51. 51.
    SAMHSA (2017) Treatment Episode Data Set (TEDS): 2005–2015. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-91, HHS Publication No. (SMA) 17-5037. Substance Abuse and Mental Health Services Administration, RockvilleGoogle Scholar
  52. 52.
    SAMSHA (2004) Treatment Episode Data Set 2002 SPSS DataGoogle Scholar
  53. 53.
    SAMHSA (2017) Treatment Episode Data Set 2015 SPSS DataGoogle Scholar
  54. 54.
    Johnston LD, Miech RA, O’Malley PM, Bachman JG, Schulenberg JE, Patrick ME (2017) Monitoring the Future national survey results on drug use: 1975–2017: Overview, key findings on adolescent drug use. Institute for Social Research, The University of Michigan, Ann ArborGoogle Scholar
  55. 55.
    Wu LT, Zhu H, Mannelli P, Swartz MS (2017) Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States. Drug Alcohol Depend 177:153–162CrossRefGoogle Scholar
  56. 56.
    Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, Hasin DS (2016) Epidemiology of DSM-5 drug use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. JAMA Psychiatry 73(1):39–47.  https://doi.org/10.1001/jamapsychiatry.2015.2132 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Blanco C, Iza M, Rodríguez-Fernández JM, Baca-García E, Wang S, Olfson M (2015) Probability and predictors of treatment-seeking for substance use disorders in the U.S. Drug Alcohol Depend 149:136–144CrossRefGoogle Scholar
  58. 58.
    Gates P, Copeland J, Swift W, Martin G (2012) Barriers and facilitators to cannabis treatment. Drug Alcohol Rev 31(3):311–319.  https://doi.org/10.1111/j.1465-3362.2011.00313.x CrossRefPubMedGoogle Scholar
  59. 59.
    van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M (2013) Facilitators and barriers in treatment seeking for cannabis dependence. Drug Alcohol Depend 133(2):776–780.  https://doi.org/10.1016/j.drugalcdep.2013.08.011 CrossRefPubMedGoogle Scholar
  60. 60.
    Budney AJ, Radonovich KJ, Higgins ST, Wong CJ (1998) Adults seeking treatment for marijuana dependence: a comparison to cocaine-dependent treatment seekers. Exp Clin Psychopharmacol 6(4):419–426CrossRefGoogle Scholar
  61. 61.
    Stephens RS, Babor TF, Kadden R, Miller M (2002) The marijuana treatment project: Rationale, design, and participant characteristics. Addiction 97(S1):109–124CrossRefGoogle Scholar
  62. 62.
    Knapp AA, Babbin SF, Budney AJ, Walker DD, Stephens RS, Scherer EA, Stanger C (2018) Psychometric assessment of the marijuana adolescent problem inventory. Addict Behav 79(4):113–119CrossRefGoogle Scholar
  63. 63.
    WHO ASSIST Working Group (2002) The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction 97(9):1183–1194CrossRefGoogle Scholar
  64. 64.
    Legleye S, Karila L, Beck F, Reynaud M (2007) Validation of the CAST, a general population cannabis abuse screening test. J Subst Use 12(4):233–242CrossRefGoogle Scholar
  65. 65.
    Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, Sellman JD (2010) An improved brief measure of cannabis misuse: the cannabis use disorders identification test-revised (CUDIT-R). Drug Alcohol Depend 110(1–2):137–143.  https://doi.org/10.1016/j.drugalcdep.2010.02.017 CrossRefPubMedGoogle Scholar
  66. 66.
    Martin G, Copeland J, Gilmour S, Gates P, Swift W (2006) The adolescent cannabis problems questionnaire (CPQ-A): psychometric properties. Addict Behav 31(12):2238–2248.  https://doi.org/10.1016/j.addbeh.2006.03.001 CrossRefPubMedGoogle Scholar
  67. 67.
    Bashford J, Flett R, J. C (2010) The cannabis use problems identification test (CUPIT): development, reliability, concurrent and predictive validity among adolescents and adults. Addiction 105(4):615–625CrossRefGoogle Scholar
  68. 68.
    White HR, Labouvie EW, Papadaratsakis V (2005) Changes in substance use during the transition to adulthood: a comparison of college students and their noncollege age peers. J Drug Issues 35(2):281–306CrossRefGoogle Scholar
  69. 69.
    Fernandez-Artamendi S, Fernández-Hermida J, Muñiz-Fernández J, Secades-Villa R, García-Fernández G (2012) Screening of cannabis-related problems among youth: the CPQ-A-S and CAST questionnaires. J Subst Abuse Treat Prev Policy 7(1):13.  https://doi.org/10.1186/1747-597x-7-13 CrossRefGoogle Scholar
  70. 70.
    Halladay J, Petker T, Fein A, Munn C, MacKillop JJSR (2018) Brief interventions for cannabis use in emerging adults: protocol for a systematic review, meta-analysis, and evidence map. Syst Rev 7(1):106.  https://doi.org/10.1186/s13643-018-0772-z CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Hughes JR, Naud S, Budney AJ, Fingar JR, Callas PW (2016) Attempts to stop or reduce daily cannabis use: an intensive natural history study. Psychol Addict Behav 30(3):389–397.  https://doi.org/10.1037/adb0000155 CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Hughes JR, Peters EN, Callas PW, Budney AJ, Livingston A (2008) Attempts to stop or reduce marijuana use in non-treatment seekers. Drug Alcohol Depend 97:180–184CrossRefGoogle Scholar
  73. 73.
    Hughes JR, Fingar JR, Budney AJ, Naud S, Helzer JE, Callas PW (2014) Marijuana use and intoxication among daily users: an intensive longitudinal study. Addict Behav 39(10):1464–1470.  https://doi.org/10.1016/j.addbeh.2014.05.024 CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lynskey M, Callaghan B, Rana U, McLaren J (2010) Systematic review of prospective studies investigating “remission” from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav 35(8):741–749CrossRefGoogle Scholar
  75. 75.
    von Sydow K, Lieb R, Pfister H, Hofler M, Sonntag H, Wittchen H (2001) The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend 64:347–361CrossRefGoogle Scholar
  76. 76.
    Budney AJ, Vandrey R, Fearer SA (2011) Cannabis (marijuana). In: Ruiz P, Strain E (eds) Lowenson & Ruiz’s substance abuse: a comprehensive textbook, 5th edn. Lippincott Williams & Wilkins, Baltimore, pp 214–237Google Scholar
  77. 77.
    Budney AJ, Vandrey RG, Stanger C (2010) Pharmacological and psychosocial interventions for cannabis use disorders. Rev Bras Psiquiatr 32(Suppl 1):S46–S55CrossRefGoogle Scholar
  78. 78.
    Cooper K, Chatters R, Kaltenthaler E, Wong R (2015) Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess 19(56):1–130.  https://doi.org/10.3310/hta19560 CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Danovitch I, Gorelick DA (2012) State of the art treatments for cannabis dependence. Psychiatric Clin of N Am 35(2):309–326.  https://doi.org/10.1016/j.psc.2012.03.003 CrossRefGoogle Scholar
  80. 80.
    Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JA (2015) Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Eval Health Prof 38(1):94–114.  https://doi.org/10.1177/0163278714529970 CrossRefPubMedGoogle Scholar
  81. 81.
    Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L (2016) Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev (5):CD005336.  https://doi.org/10.1002/14651858.CD005336.pub4
  82. 82.
    Sherman BJ, McRae-Clark AL (2016) Treatment of cannabis use disorder: current ccience and future outlook. Pharmacotherapy 36(5):511–535.  https://doi.org/10.1002/phar.1747 CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Budney AJ, Stanger C, Knapp AA, Walker DD (2018) Status update on the treatment of cannabis use disorder. In: Winters KC, Sabet KA (eds) Contemporary health issues on marijuana. Oxford University Press, New York, pp 236–255Google Scholar
  84. 84.
    Parmar A, Sarkar S (2017) Brief interventions for cannabis use disorders. Rev Addict Dis Treat 16(2):80–93CrossRefGoogle Scholar
  85. 85.
    Budney AJ, Borodovsky JT, Marsch LA, Knapp AA (In press) Technological innovations in addiction treatment. In: Danovitch I, Mooney L (eds) The Assessment and Treatment of Addiction: Best Practices and New Frontiers. ElsevierGoogle Scholar
  86. 86.
    Marsch LA, Carroll KM, Kiluk BD (2014) Technology-based interventions for the treatment and recovery management of substance use disorders: a JSAT special issue. J Subst Abuse Treat 46(1):1–4.  https://doi.org/10.1016/j.jsat.2013.08.010 CrossRefPubMedGoogle Scholar
  87. 87.
    Schaub MP, Wenger A, Berg O, Beck T, Stark L, Buehler E, Haug S (2015) A web-based self-help intervention with and without chat counseling to reduce cannabis use in problematic cannabis users: three-arm randomized controlled trial. J Med Internet Res 17(10):e232.  https://doi.org/10.2196/jmir.4860 CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Hogue A, Henderson CE, Ozechowski TJ, Robbins MS (2014) Evidence base on outpatient behavioral treatments for adolescent substance use: updates and recommendations 2007–2013. J Clin Child Adolesc Psychol 43(5):695–720.  https://doi.org/10.1080/15374416.2014.915550 CrossRefPubMedGoogle Scholar
  89. 89.
    Simpson AK, Magid V (2016) Cannabis use disorder in adolescence. Child Adolesc Psychiatr Clin N Am 25(3):431–443.  https://doi.org/10.1016/j.chc.2016.03.003 CrossRefPubMedGoogle Scholar
  90. 90.
    Stanger C, Lansing AH, Budney AJ (2016) Advances in research on contingency management for adolescent substance use. Child Adolesc Psychiatr Clin N Am 25(4):645–659.  https://doi.org/10.1016/j.chc.2016.05.002 CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Tanner-Smith EE, Wilson SJ, Lipsey MW (2013) The comparative effectiveness of outpatient treatment for adolescent substance abuse: a meta-analysis. J Subst Abuse Treat 44:145–158CrossRefGoogle Scholar
  92. 92.
    Waldron HB, Turner CW (2008) Evidence-based psychosocial treatments for adolescent substance abuse. J Clin Child Adolesc Psychol 37(1):238–261.  https://doi.org/10.1080/15374410701820133 CrossRefPubMedGoogle Scholar
  93. 93.
    Winters KC, Tanner-Smith EE, Bresani E, Meyers K (2014) Current advances in the treatment of adolescent drug use. Adolesc Health Med Ther 5:199–210.  https://doi.org/10.2147/AHMT.S48053 CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Winters KC, Botzet AM, Fahnhorst T (2011) Advances in adolescent substance abuse treatment. Curr Psychiatry Rep 13(5):416–421.  https://doi.org/10.1007/s11920-011-0214-2 CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Hogue A, Henderson CE, Becker SJ, Knight DK (2018) Evidence base on outpatient behavioral treatments for adolescent substance use, 2014–2017: outcomes, treatment delivery, and promising horizons. J Clin Child Adolesc Psychol 47(4):499–526.  https://doi.org/10.1080/15374416.2018.1466307 CrossRefPubMedGoogle Scholar
  96. 96.
    Liddle HA, Rowe CL, Dakof GA, Ungaro RA, Henderson CE (2004) Early intervention for adolescent substance abuse: pretreatment to posttreatment outcomes of a randomized clinical trial comparing multidimensional family therapy and peer group treatment. J Psychoactive Drugs 36(1):49–63CrossRefGoogle Scholar
  97. 97.
    Marsch LA, Borodovsky JT (2016) Technology-based interventions for preventing and treating substance use among youth. Child Adolesc Psychiatric Clin N Am 25(4):755–768.  https://doi.org/10.1016/j.chc.2016.06.005 CrossRefGoogle Scholar
  98. 98.
    Gorelick DA (2016) Pharmacological treatment of cannabis-related disorders: a narrative review. Curr Pharm Des 22(42):6409–6419.  https://doi.org/10.2174/1381612822666160822150822 CrossRefPubMedGoogle Scholar
  99. 99.
    Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR (2017) A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 177:249–257.  https://doi.org/10.1016/j.drugalcdep.2017.04.020 CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Copeland J, Pokorski I (2016) Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. Subst Abuse Rehabil 7:41–53.  https://doi.org/10.2147/SAR.S89857 CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Mason BJ, Mustafa A, Filbey F, Brown ES (2016) Novel pharmacotherapeutic interventions for cannabis use disorder. Curr Addict Rep 3(2):214–220CrossRefGoogle Scholar
  102. 102.
    Denis C, Lavie E, Fatseas M, Auriacombe M (2006) Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 3.  https://doi.org/10.1002/14651858.CD005336.pub2
  103. 103.
    Hall W, Lynskey M (2016) Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. Lancet Psychiatry 3(9):900–906CrossRefGoogle Scholar
  104. 104.
    Wen H, Hockenberry JM, Druss BG (2018) The effect of medical marijuana laws on marijuana-related attitude and perception among US adolescents and young adults. Prev Sci.  https://doi.org/10.1007/s11121-018-0903-8 CrossRefPubMedGoogle Scholar
  105. 105.
    Hasin DS (2017) US epidemiology of cannabis use and associated problems. Neuropsychopharmacology 43:195.  https://doi.org/10.1038/npp.2017.198 CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Carlini BH, Garrett SB, Harwick RM (2017) Beyond joints and brownies: Marijuana concentrates in the legal landscape of WA State. Int J Drug Policy 42:26–29.  https://doi.org/10.1016/j.drugpo.2017.01.004 CrossRefPubMedGoogle Scholar
  107. 107.
    Borodovsky JT, Crosier BS, Lee DC, Sargent JD, Budney AJ (2016) Smoking, vaping, eating: is legalization impacting the way people use cannabis? Int J Drug Policy 36:141–147.  https://doi.org/10.1016/j.drugpo.2016.02.022 CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ (2017) Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol 41 1–17.  https://doi.org/10.1093/jat/bkx012 CrossRefGoogle Scholar
  109. 109.
    Loflin M, Earleywine M (2014) A new method of cannabis ingestion: the dangers of dabs? Addict Behav 39(10):1430–1433.  https://doi.org/10.1016/j.addbeh.2014.05.013 CrossRefPubMedGoogle Scholar
  110. 110.
    Volkow N, Baler R, Compton W, Weiss S (2014) Adverse health effects of marijuana use. N Engl J Med 370(23):2219–2227CrossRefGoogle Scholar
  111. 111.
    Paul CL, Mee KJ, Judd TM, Walsh RA, Tang A, Penman A, Girgis A (2010) Anywhere, anytime: retail access to tobacco in New South Wales and its potential impact on consumption and quitting. Soc Sci Med 71(4):799–806.  https://doi.org/10.1016/j.socscimed.2010.05.011 CrossRefPubMedGoogle Scholar
  112. 112.
    Casswell S, Morojele N, Williams PP, Chaiyasong S, Gordon R, Gray-Philip G, Viet Cuong P, MacKintosh AM, Halliday S, Railton R, Randerson S, Parry CDH (2018) The alcohol environment protocol: a new tool for alcohol policy. Drug Alcohol Rev.  https://doi.org/10.1111/dar.12654 CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Bickel WK, Johnson MW, Koffarnus MN, MacKillop J, Murphy JG (2014) The behavioral economics of substance use disorders: reinforcement pathologies and their repair. Annu Rev Clin Psychol 10:641–677.  https://doi.org/10.1146/annurev-clinpsy-032813-153724 CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Borodovsky JT, Lee DC, Crosier BS, Gabrielli JL, Sargent JD, Budney AJ (2017) U.S. cannabis legalization and use of vaping and edible products among youth. Drug Alcohol Depend 177:299–306.  https://doi.org/10.1016/j.drugalcdep.2017.02.017 CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Lee DC, Crosier BS, Borodovsky JT, Sargent JD, Budney AJ (2016) Online survey characterizing vaporizer use among cannabis users. Drug Alcohol Depend 159:227–233.  https://doi.org/10.1016/j.drugalcdep.2015.12.020 CrossRefPubMedGoogle Scholar
  116. 116.
    Borodovsky JT, Budney AJ (2017) Legal cannabis laws, home cultivation, and use of edible cannabis products: a growing relationship? Int J Drug Policy 50:102–110.  https://doi.org/10.1016/j.drugpo.2017.09.014 CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Caulkins JP, Kilmer B, MacCoun RJ, Pacula RL, Reuter PH (2012) Design considerations for legalizing cannabis: lessons inspired by analysis of California’s proposition 19. Addiction 107(5):865–871CrossRefGoogle Scholar
  118. 118.
    Pacula RL, Kilmer B, Wagenaar AC, Chaloupka FJ, Caulkins JP (2014) Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health 104(6):1021–1028.  https://doi.org/10.2105/AJPH.2013.301766 CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Chaloupka FJ, Straif K, Leon ME (2010) Effectiveness of tax and price policies in tobacco control. Tobacco Control.  https://doi.org/10.1136/tc.2010.039982 CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Chaloupka FJ, Cummings KM, Morley CP, Horan JK (2002) Tax, price and cigarette smoking: Evidence from the tobacco documents and implications for tobacco company marketing strategies. Tob Control 11(suppl 1):I62–I72.  https://doi.org/10.1136/tc.11.suppl_1.i62 CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Farrell S, Manning WG, Finch MD (2003) Alcohol dependence and the price of alcoholic beverages. J Health Econ 22(1):117–147CrossRefGoogle Scholar
  122. 122.
    DiFranza JR, Wellman RJ, Sargent JD, Weitzman M, Hipple BJ, Winickoff JP, Tobacco Consortium CfCHRotAAoP (2006) Tobacco promotion and the initiation of tobacco use: assessing the evidence for causality. Pediatrics 117(6):e1237–e1248.  https://doi.org/10.1542/peds.2005-1817 CrossRefPubMedGoogle Scholar
  123. 123.
    Pechmann C, Knight SJ (2002) An experimental investigation of the joint effects of advertising and peers on adolescents’ beliefs and intentions about cigarette consumption. J Consum Res 29(1):5–19.  https://doi.org/10.1086/339918 CrossRefGoogle Scholar
  124. 124.
    Landman A, Cortese DK, Glantz S (2008) Tobacco industry sociological programs to influence public beliefs about smoking. Soc Sci Med 66(4):970–981.  https://doi.org/10.1016/j.socscimed.2007.11.007 CrossRefPubMedPubMedCentralGoogle Scholar
  125. 125.
    Evans N, Farkas A, Gilpin E, Berry C, Pierce JP (1995) Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking. J Natl Cancer Inst 87(20):1538–1545CrossRefGoogle Scholar
  126. 126.
    Biener L, Siegel M (2000) Tobacco marketing and adolescent smoking: more support for a causal inference. Am J Public Health 90(3):407–411CrossRefGoogle Scholar
  127. 127.
    DeWit DJ, Adlaf EM, Offord DR, Ogborne AC (2000) Age at first alcohol use: a risk factor for the development of alcohol disorders. Am J Psychiatry 157(5):745–750.  https://doi.org/10.1176/appi.ajp.157.5.745 CrossRefPubMedGoogle Scholar
  128. 128.
    Chen C-Y, O’Brien MS, Anthony JC (2005) Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. Drug Alcohol Depend 79:11–22CrossRefGoogle Scholar
  129. 129.
    Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen H-U (2008) The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 103(3):439–449.  https://doi.org/10.1111/j.1360-0443.2007.02064.x CrossRefPubMedGoogle Scholar
  130. 130.
    Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC (2008) Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. Addiction 103(8):1361–1370.  https://doi.org/10.1111/j.1360-0443.2008.02246.x CrossRefPubMedGoogle Scholar
  131. 131.
    Agrawal A, Grant JD, Waldron M, Duncan AE, Scherrer JF, Lynskey MT, Madden PA, Bucholz KK, Heath AC (2006) Risk for initiation of substance use as a function of age of onset of cigarette, alcohol and cannabis use: findings in a midwestern female twin cohort. Prev Med 43(2):125–128.  https://doi.org/10.1016/j.ypmed.2006.03.022 CrossRefPubMedGoogle Scholar
  132. 132.
    D’Amico EJ, Miles JNV, Tucker JS (2015) Gateway to curiosity: medical marijuana ads and intention and use during middle school. Psychol Addict Behav 29(3):613–619.  https://doi.org/10.1037/adb0000094 CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Roditis ML, Delucchi K, Chang A, Halpern-Felsher B (2016) Perceptions of social norms and exposure to pro-marijuana messages are associated with adolescent marijuana use. Prev Med 93:171–176.  https://doi.org/10.1016/j.ypmed.2016.10.013 CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min SJ, Sakai JT (2014) Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003-11. Drug Alcohol Depend 140:145–155.  https://doi.org/10.1016/j.drugalcdep.2014.04.016 CrossRefPubMedPubMedCentralGoogle Scholar
  135. 135.
    D’Amico EJ, Rodriguez A, Tucker JS, Pedersen ER, Shih RA (2018) Planting the seed for marijuana use: changes in exposure to medical marijuana advertising and subsequent adolescent marijuana use, cognitions, and consequences over seven years. Drug Alcohol Depend 188:385–391.  https://doi.org/10.1016/drugalcdep.2018.03.031 CrossRefPubMedGoogle Scholar
  136. 136.
    Barry RA, Glantz S (2016) A public health framework for legalized retail marijuana based on the US experience: avoiding a new tobacco industry. PLoS Med 13(9):e1002131.  https://doi.org/10.1371/journal.pmed.1002131 CrossRefPubMedPubMedCentralGoogle Scholar
  137. 137.
    Caulkins JP, Kilmer B, Kleiman MAR (2016) Marijuana legalization: What everyone needs to know, 2 edn. Oxford University Press, New York.  https://doi.org/10.7249/CB525-1 CrossRefGoogle Scholar
  138. 138.
    Kilmer B (2014) Policy designs for cannabis legalization: starting with the eight Ps. Am J Drug Alcohol Abuse 40(4):259–261.  https://doi.org/10.3109/00952990.2014.894047 CrossRefPubMedGoogle Scholar
  139. 139.
    Richter KP, Levy S (2014) Big marijuana–lessons from big tobacco. N Engl J Med 371(5):399–401.  https://doi.org/10.1056/NEJMp1406074 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Center for Technology and Behavioral Health, Department of PsychiatryGeisel School of Medicine at DartmouthLebanonUSA
  2. 2.Department of PsychiatryWashington University School of MedicineSt. LouisUSA

Personalised recommendations